BPC May 14 update

​Allogene ALLO shares +36% on promising ASCO abstract data

Price and Volume Movers

Allogene Therapeutics, Inc. (NASDAQ: ALLO) was the best performing stock following the release of ASCO abstracts late-Wednesday. Shares closed Thursday up 36% to $42.12 with data from its Phase 1 trial of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma (NHL) showing an overall response rate (ORR) of 78%.

Cellectis S.A. (NASDAQ: CLLS) shares closed up 27% to $17.41. Baird analysts raised their price target to $22 from $20 while maintaining an Outperform rating.

CytomX Therapeutics (NASDAQ:CTMX) shares slumped 36% to $9.23 with investors disappointed with the data from the abstract of its probody theaputic, CX-072. Data from the Phase 2 Proclaim trial in patients with solid tumors showed a response rate of 8.8% (n=10/114), all partials responses.

Novus Therapeutics, Inc. (NASDAQ:NVUS) shares closed up 18% to $1.05. Data from its Phase 2a trial in children with acute otitis media are set to be announced early next month.

TG Therapeutics, Inc. (NASDAQ:TGTX) announced that it intends to offer and sell 6m shares of its common stock in an underwritten public offering.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:


Diffusion Pharmaceuticals Inc. (DFFN): $1.02; +28%.

AIM ImmunoTech Inc. (AIM): $2.94; +25%.

IMARA Inc. (IMRA): $25.95; +20%.

Plus Therapeutics, Inc. (PSTV): $2.13; +17%.


Caladrius Biosciences, Inc. (CLBS): $1.70; -21%.

Axcella Health Inc. (AXLA): $4.39; -18%.

Compugen Ltd. (CGEN): $11.57; -17%.

Arvinas, Inc. (ARVN): $44.19; -13%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ACER – Acer Therapeutics Inc.
Urea cycle disorder (UCD)

NDA Filing NDA filing due early 2021.
$31.5 million

ACHV – Achieve Life Sciences Inc.
Cytisine - ORCA-2
Smoking cessation

Phase 3 Phase 3 trial to be initiated 2H 2020.
$15.3 million

ADAP – Adaptimmune Therapeutics plc
Hepatocellular carcinoma

Phase 1 Phase 1 presentation at ILC August 25-28, 2020.
$1.4 billion

BHC – Bausch Health Companies Inc.
Allergic conjunctivitis

PDUFA CRL issued July 12, 2019. NDA resubmitted with new PDUFA date of August 10, 2020.
$6.6 billion

BTAI – BioXcel Therapeutics Inc.
Bipolar disorder - agitation

Phase 3 Phase 3 data due July 2020.
$941 million

CLBS – Caladrius Biosciences Inc.
Coronary microvascular dysfunction (CMD)

Phase 2 Phase 2b trial to be initiated fall of 2020.
$24.4 million

DARE – Dare Bioscience Inc.
Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD)

Phase 2b Phase 2b data due 2021.
$28 million

GLMD – Galmed Pharmaceuticals Ltd.
Aramchol - ARMOR
Non-Alcoholic Steatohepatitis (NASH)

Phase 3 Phase 3 initial data due 2H 2023.
$100.5 million

HOOK – HOOKIPA Pharma Inc.
Cytomegalovirus (CMV)

Phase 2 Phase 2 safety and immunogenicity data due July 2020, with efficacy data due 2H 2020.
$279.8 million

ITRM – Iterum Therapeutics plc
Uncomplicated urinary tract infections (uUTI)

Phase 3 Phase 3 data due May 2020.
$62.6 million

ITRM – Iterum Therapeutics plc
Complicated urinary tract infections (cUTI)

Phase 3 Phase 3 data due 2Q 2020.
$62.6 million

MRSN – Mersana Therapeutics Inc.
Non-small cell lung cancer (NSCLC) adenocarcinoma and ovarian cancer

Phase 1 Phase 1 trial initiation announced May 14, 2020.
$1.3 billion

NK – NantKwest Inc.
t-haNK and N-803
Pancreatic cancer

Phase 2 Phase 2 trial to be initiated in 2020.
$664 million

ONTX – Onconova Therapeutics Inc.
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Phase 3 Phase 3 data due 2H 2020.
$70.4 million